Endogenous Opiates and Behavior: 2015

Bodnar, Richard J.

doi:10.1016/j.peptides.2016.12.004

Cited by 49 publications

(33 citation statements)

References 1,406 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, a growing body of evidence has suggested that the opioidergic system plays a key role in memory processing . It has already been shown that endogenous opioid peptides and opioid receptor agonists are able to impair memory consolidation in animal models of memory . Our previous studies also revealed that morphine dose‐dependently impaired memory consolidation .…”

Section: Introductionmentioning

confidence: 85%

Effect of pretreatment with intracerebroventricular injection of minocycline on morphine‐induced memory impairment in passive avoidance test: Role of P‐CREB and c‐Fos expression in the dorsal hippocampus and basolateral amygdala regions

Hamidkhaniha

Bashiri

Omidi

et al. 2019

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Summary Minocycline as a member of the tetracycline family is a lipophilic broad‐spectrum antibiotic, which can display some non‐antibiotic properties such as antioxidant, antiapoptosis, neuroprotection and modulation of pharmacological traits of drugs of abuse (ie, reward, sensitization and/or analgesia). Thus, the aim of the present study was to investigate the effect of intracerebroventricular (ICV) injection of minocycline on morphine‐induced memory impairment and motor function in male Wistar rats. The behavioural responses were measured by a passive avoidance test for evaluating memory, and in the open field for studying motor function. Furthermore, the expression of Phospho‐cAMP response element‐binding protein (P‐CREB) and c‐Fos were assessed using immunohistochemistry in the dorsal hippocampus and basolateral amygdala (BLA). Our results showed that morphine dose‐dependently impairs memory consolidation, but not motor function. Maximum effect was achieved with morphine at dose of 5 mg/kg. Pretreatment with ICV injection of minocycline (50 μg/rat) prevented morphine‐induced memory impairment, but there was no effect on motor function. The results of immunohistochemistry analysis demonstrated that morphine decreased expression of P‐CREB positive cells compared to saline control group in the BLA, but not in the dorsal hippocampus. On the other hand, pretreatment of animals with ICV injection of minocycline increased the expression of P‐CREB in both brain areas. Moreover, there was no significant change in the expression of c‐Fos positive cells in above‐mentioned regions. In summary, our results indicated that pretreatment with ICV injection of minocycline prevented morphine‐induced memory impairment and increased P‐CREB expression in the dorsal hippocampus and BLA, which may explain its memory improvement property.

show abstract

Section: Introductionmentioning

confidence: 85%

Effect of pretreatment with intracerebroventricular injection of minocycline on morphine‐induced memory impairment in passive avoidance test: Role of P‐CREB and c‐Fos expression in the dorsal hippocampus and basolateral amygdala regions

Hamidkhaniha

Bashiri

Omidi

et al. 2019

Clin Exp Pharma Physio

View full text Add to dashboard Cite

show abstract

“…[30]), the expression of ENK, DOPr, and MOPr is ubiquitous. Indeed, ENK are distributed among the central, peripheral, and autonomous nervous systems, as well as in endocrine tissues (adrenal medulla, endocrine pancreas) and their target organs (liver, skin, bones, and lungs) [31, 32].…”

Section: Enkephalins and Their Opioid Receptorsmentioning

confidence: 99%

Enkephalins: Endogenous Analgesics with an Emerging Role in Stress Resilience

et al. 2017

View full text Add to dashboard Cite

Psychological stress is a state of mental or emotional strain or tension that results from adverse or demanding circumstances. Chronic stress is well known to induce anxiety disorders and major depression; it is also considered a risk factor for Alzheimer's disease. Stress resilience is a positive outcome that is associated with preserved cognition and healthy aging. Resilience presents psychological and biological characteristics intrinsic to an individual conferring protection against the development of psychopathologies in the face of adversity. How can we promote or improve resilience to chronic stress? Numerous studies have proposed mechanisms that could trigger this desirable process. The roles of enkephalin transmission in the control of pain, physiological functions, like respiration, and affective disorders have been studied for more than 30 years. However, their role in the resilience to chronic stress has received much less attention. This review presents the evidence for an emerging involvement of enkephalin signaling through its two associated opioid receptors, μ opioid peptide receptor and δ opioid peptide receptor, in the natural adaptation to stressful lifestyles.

show abstract

“…Nalbuphine (NAL) has been recognized as a moderate‐efficacy partial agonist or antagonist of the μ‐opioid receptor and as a high‐efficacy partial agonist of the κ‐opioid receptor with its low affinity for either the δ‐opioid receptor or the σ receptor (Al‐Hasani & Bruchas, ; Barry & Zuo, ; Bodnar, ; Raghav, Jain, Dhawan, Roy, & Kumar, ). It can relieve moderate to severe pain and itching, the mechanisms are thought to be its binding to opioid receptors (Bodnar, ; Chen et al, ; Davis, Fernandez, Regel, & McPherson, ; Mathur et al, ; Pereira & Stander, ; Reszke & Szepietowski, ; Tubog, Harenberg, Buszta, & Hestand, ; Withey, Paronis, & Bergman, ). Alternatively, it can be used to balance anesthesia, for preoperative and postoperative analgesia, and for obstetrical analgesia (Bindra, Kumar, & Jindal, ; Kim, Kim, Lee, Chung, & Hong, ).…”

Section: Introductionmentioning

confidence: 99%

“…. It can relieve moderate to severe pain and itching, the mechanisms are thought to be its binding to opioid receptors (Bodnar, 2017;Chen et al, 2014;Davis, Fernandez, Regel, & McPherson, 2018;Mathur et al, 2017;Pereira & Stander, 2018;Reszke & Szepietowski, 2018;Tubog, Harenberg, Buszta, & Hestand, 2018;Withey, Paronis, & Bergman, 2018). Alternatively, it can be used to balance anesthesia, for preoperative and postoperative analgesia, and for obstetrical analgesia (Bindra, Kumar, & Jindal, 2018;Kim, Kim, Lee, Chung, & Hong, 2011).…”

mentioning

confidence: 99%

Effectiveness of nalbuphine, a κ‐opioid receptor agonist and μ‐opioid receptor antagonist, in the inhibition of I_Na, I_K(M), and I_K(erg) unlinked to interaction with opioid receptors

Liu

Hsiao

Wang

et al. 2019

Drug Development Research

View full text Add to dashboard Cite

Nalbuphine (NAL) is recognized as a mixer with the κ‐opioid receptor agonist and the μ‐opioid receptor antagonist. However, whether this drug causes any modifications in neuronal ionic currents is unclear. The effects of NAL on ionic currents in mHippoE‐14 hippocampal neurons were investigated. In the whole‐cell current recordings, NAL suppressed the peak amplitude of voltage‐gated Na+ current (INa) with an IC50 value of 1.9 μM. It shifted the steady‐state inactivation curve of peak INa to the hyperpolarized potential, suggesting that there is the voltage dependence of NAL‐mediated inhibition of peak INa. In continued presence of NAL, subsequent application of either dynorphin A1‐13 (1 μM) or naloxone (30 μM) failed to modify its suppression of peak INa. Tefluthrin (Tef; 10 μM), a pyrethroid known to activate INa, increased peak INa with slowed current inactivation; however, further application of NAL suppressed Tef‐mediated suppression of peak INa followed by an additional slowing of current inactivation. In addition, NAL suppressed the amplitude of M‐type K+ current [IK(M)] with an IC50 value of 5.7 μM, while it slightly suppressed erg‐mediated and delayed‐rectifier K+ currents. In the inside‐out current recordings, NAL failed to modify the activity of large‐conductance Ca2+‐activated K+ channels. In differentiated NG108‐15 neuronal cells, NAL also suppressed the peak INa, and subsequent addition of Tef reversed NAL‐induced suppression of INa. Our study highlights the evidence that in addition to modulate opioid receptors, NAL has the propensity to interfere with ionic currents including INa and IK(M), thereby influencing the functional activities of central neurons.

show abstract

Endogenous Opiates and Behavior: 2015

Cited by 49 publications

References 1,406 publications

Effect of pretreatment with intracerebroventricular injection of minocycline on morphine‐induced memory impairment in passive avoidance test: Role of P‐CREB and c‐Fos expression in the dorsal hippocampus and basolateral amygdala regions

Effect of pretreatment with intracerebroventricular injection of minocycline on morphine‐induced memory impairment in passive avoidance test: Role of P‐CREB and c‐Fos expression in the dorsal hippocampus and basolateral amygdala regions

Enkephalins: Endogenous Analgesics with an Emerging Role in Stress Resilience

Effectiveness of nalbuphine, a κ‐opioid receptor agonist and μ‐opioid receptor antagonist, in the inhibition of I_Na, I_K(M), and I_K(erg) unlinked to interaction with opioid receptors

Contact Info

Product

Resources

About

Endogenous Opiates and Behavior: 2015

Cited by 49 publications

References 1,406 publications

Effect of pretreatment with intracerebroventricular injection of minocycline on morphine‐induced memory impairment in passive avoidance test: Role of P‐CREB and c‐Fos expression in the dorsal hippocampus and basolateral amygdala regions

Effect of pretreatment with intracerebroventricular injection of minocycline on morphine‐induced memory impairment in passive avoidance test: Role of P‐CREB and c‐Fos expression in the dorsal hippocampus and basolateral amygdala regions

Enkephalins: Endogenous Analgesics with an Emerging Role in Stress Resilience

Effectiveness of nalbuphine, a κ‐opioid receptor agonist and μ‐opioid receptor antagonist, in the inhibition of INa, IK(M), and IK(erg) unlinked to interaction with opioid receptors

Contact Info

Product

Resources

About

Effectiveness of nalbuphine, a κ‐opioid receptor agonist and μ‐opioid receptor antagonist, in the inhibition of I_Na, I_K(M), and I_K(erg) unlinked to interaction with opioid receptors